Rivaroxaban data abound at ESC 2018

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify